Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR156597 in diffuse cutaneous systemic sclerosis
2016-001028-80Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2016
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of romilkimab in systemic sclerosis (SSc), sponsored by Sanofi. Started Jul 2016; status: completed.
02
Drugs
romilkimab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2016-001028-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001028-80.